Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
50.78
-0.68 (-1.32%)
At close: Nov 20, 2026, 4:00 PM EST
52.48
+1.70 (3.35%)
After-hours: Nov 20, 2026, 7:38 PM EST
Cytokinetics Revenue
Cytokinetics had revenue of $47.56M in the quarter ending September 30, 2026, with 2,356.46% growth. This brings the company's total for the last twelve months to $113.29M, up 29.90% year-over-year. In the year 2025, Cytokinetics had annual revenue of $88.04M with 376.56% growth. That makes Cytokinetics the 21,779th largest company in the world by revenue and 3,207th in the United States.
Revenue (ttm)
$113.29M
Revenue Growth
+29.90%
P/S Ratio
62.44
Revenue / Employee
$168,337
Employees
673
Market Cap
7.07B
Revenue by Segment
- Milestone 79.35M 90.1%
- Research and Development 8.69M 9.9%
Fiscal year ended Dec 31, 2025 See the full Cytokinetics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 88.04M | 69.57M | 376.56% |
| Dec 31, 2024 | 18.47M | 10.94M | 145.34% |
| Dec 31, 2023 | 7.53M | -87.06M | -92.04% |
| Dec 31, 2022 | 94.59M | 24.16M | 34.30% |
| Dec 31, 2021 | 70.43M | 14.60M | 26.15% |
| Dec 31, 2020 | 55.83M | 28.96M | 107.79% |
| Dec 31, 2019 | 26.87M | -4.63M | -14.71% |
| Dec 31, 2018 | 31.50M | 18.13M | 135.64% |
| Dec 31, 2017 | 13.37M | -93.04M | -87.44% |
| Dec 31, 2016 | 106.41M | 77.75M | 271.30% |
| Dec 31, 2015 | 28.66M | -18.28M | -38.95% |
| Dec 31, 2014 | 46.94M | 16.29M | 53.16% |
| Dec 31, 2013 | 30.65M | 23.09M | 305.45% |
| Dec 31, 2012 | 7.56M | 3.56M | 88.98% |
| Dec 31, 2011 | 4.00M | 1.42M | 55.22% |
| Dec 31, 2010 | 2.58M | -78.96M | -96.84% |
| Dec 31, 2009 | 81.54M | 69.12M | 556.51% |
| Dec 31, 2008 | 12.42M | -1.20M | -8.82% |
| Dec 31, 2007 | 13.62M | 10.50M | 335.63% |
| Dec 31, 2006 | 3.13M | -5.79M | -64.91% |
| Dec 31, 2005 | 8.91M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Corcept Therapeutics | 963.65M |
| Axsome Therapeutics | 865.27M |
| Protagonist Therapeutics | 551.69M |
| Twist Bioscience | 459.43M |
| Rhythm Pharmaceuticals | 280.75M |
| ImmunityBio | 182.57M |
| CG Oncology | 6.17M |
CYTK News
- 1 day ago - Cytokinetics price target lowered to $100 from $103 at JPMorgan - TheFly
- 5 days ago - Cytokinetics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 5 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - Cytokinetics Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 6 days ago - Cytokinetics announces FDA approval for Myqorzo sNDA - TheFly
- 6 days ago - Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM - GlobeNewsWire
- 11 days ago - Cytokinetics Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 12 days ago - Cytokinetics announces additional aficamten data in hypertrophic cardiomyopathy - TheFly